about
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationIn vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancerGenetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Albert Gris-Oliver
@en
Albert Gris-Oliver
@nl
type
label
Albert Gris-Oliver
@en
Albert Gris-Oliver
@nl
prefLabel
Albert Gris-Oliver
@en
Albert Gris-Oliver
@nl
P31
P496
0000-0003-1802-9541